SK Bioscienceโ Honored with Minister of Health and Welfare โคAward for Vaccine Innovationโ and Public Health Contributions
Seoul, Korea – โ SK Bioscience โคhasโ been recognized for its notable contributions to โฃnationalโ health security and global public health with the Minister ofโฃ Health andโฃ Welfare Award โat theโ ‘2025 Health Industry Performance Exchange’ held in Seoul on the 27th. The awardโ acknowledges โขthe company’s dedication to vaccine self-sufficiency and strengthening infectious disease response โcapabilities.
The annual event, hosted by the โขMinistry ofโค Health and Welfare and the Korea Health Industry Development โขInstitute, celebrates innovation withinโ the health industry and honors key contributors.SK Bioscience was specifically lauded as an “innovativeโค pharmaceutical company” for its R&D-driven advancements in vaccine development and platform technology.
SK Bioscience has playedโ a pivotal role in bolstering Korea’s โฃvaccine independence with โthe development of Sky cell Flu, the nation’s first cell culture-based flu vaccine, ensuring a consistent supply. โ The company further solidifiedโฃ this position withโฃ SkyCovid One, Korea’s first domestically produced COVID-19 vaccine, developed โคusing its own platform technology and afterward listed on the World Health Institution’s Emergency Use List (EUL). โข
Beyond COVID-19 and influenza,SK โขBioscience continues to protect public health through its established portfolio of vaccines including Sky Varicella โ(chickenpox) and Skyโค Zoster (shingles).
The โcompany is actively workingโ with the Korea Disease Control and Prevention Agency on a cell culture-basedโ avian influenza vaccine, aiming to further enhance national โคpreparedness. SK โฃbioscience is also expandingโ its global impact through collaborations with โorganizations likeโ the Gates Foundation, CEPI, and Gavi, developing vaccines against diseases like โคJapanese โencephalitis and Lassa fever. โ Strategic โฃpartnerships with Sanofi for next-generation โpneumococcal vaccineโค developmentโฃ and โthe acquisitionโ of German company IDT Biologica to โstrengthen CDMO capabilities, alongside investments in mRNA โtechnology, demonstrate the company’s commitment to becoming a leading globalโ vaccine partner.
Yoon Hyeok, head ofโ the Bio Regulatory Management โฃTeam โคat SK Bioscience, also received a commendationโค for his โฃcontributions to supporting domestic vaccine development, facilitatingโ global clinical trials, and establishing robust biosafety systems.
“This award is a meaningfulโ achievement as theโ country recognizes our efforts to improve publicโฃ health and expand global vaccine accessibility,” said Jae-yong ahn, CEO ofโ SK Bioscience. “We will continue to strengthen vaccine sovereignty as aโ technology-based innovative pharmaceutical company and grow into aโ company that contributes to a healthier world.”